Navigation Links
Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
Date:9/30/2010

/i>eimear.obrien@ucb.comAndrea Levin, Senior Manager, Communications & PR, CNS, UCB, Inc.Office: 770.970.8352 / Mobile: 404.483.7329 / Email: andrea.levin@ucb.comAbout Neupro® in EuropeNeupro® (rotigotine) is approved in the European Union for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occurs. Neupro® is also approved in the European Union for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Neupro® in Europe Important Safety InformationNeupro® is contraindicated in case of hypersensitivity to the active substance or to any of its excipients, and in case of magnetic resonance imaging (MRI) or cardioversion. Neupro® should be removed if the patient has to undergo MRI or cardioversion.

It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy.

Neupro® has been associated with somnolence episodes of sudden sleep onset episodes. Patients treated with dopamine agonists including Neupro®, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality.

Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore it is recommended to taper treatment.

Neupro® contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain sus
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
2. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
5. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
6. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... HYDERABAD, India , July 31, 2015 /PRNewswire/ ... Billing and CRM solutions for video, data and cloud ... (PoC) with a leading pharma giant for Internet ... managing different IoT applications offered on subscription model. ... Pharma giant is striving for business ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... ARAY ), the premier radiation oncology company, announced ... UBS Global Life Sciences Conference in New York on Tuesday, ... A live webcast of the presentation will be available ... site at http://www.accuray.com . The webcast replay of the ...
... 16, 2011 The U.S.-Russia Business Council is pleased to ... today to establish two new joint ventures in Russia. These ... fastest-growing markets while enhancing Russia,s power generation and healthcare sectors. ... more than US$10 – 15 billion in sales, GE will ...
Cached Medicine Technology:USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia 2
(Date:8/1/2015)... ... ... Calvary Hospital today announced that it is embarking on a yearlong restoration ... bring this Torah – dating from 1880 – back to kosher status, so that ... Scroll No. 515, from the town of Taus-Domazlice, is on permanent loan to Calvary ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, ... who are thought to have been behind the attack on Anthem Inc. which resulted ... zero day exploits, watering hole attacks and spear phishing campaigns. , For ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:8/1/2015)... ... ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction ... stepping off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 ... greeted by friends and family. He visited CCAR and left an inspirational message to ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... week's BMJ have their say on whether patients should have ... ,The medical profession is concerned that, in the proposed ... input from the patient, and this is not being made ... Alan Hassey in a letter to this week's journal. ...
... Remedies Ltd today said it has filed its ... fixed dose combination used in the treatment of ... combination, active against multi-resistant strains of both gram- ... coverage of bactericidal activity, it informed the Bombay ...
... journal Substance Abuse Treatment, Prevention and policy unwinds that the ... alcohol dependent patients better for a long term. ... who abstain from drinking alcohol is more than the patients ... at the medical school. Also the abstinence is longer ...
... investigation has revealed that some homeopathic clinics advice people ... of the world.// ,People planning on taking ... avoid homeopathic remedies that are claiming to prevent malaria, ... ,It was reported that every year almost around ...
... Essar group and the Jindal group have committed to ... medicare for people leaving Below Poverty Line in Jharkhand. ... the Sarva Swasthya Mission trust is being formed by ... an official release said here today Independently run by ...
... selected Indian ministry of health and family welfare for ... stance on health promotion and tobacco control"//. ,Minister ... the award at a ceremony during the World Conference ... said. ,The award has been conferred on ...
Cached Medicine News:Health News:Electronic Patient Record "Serious Threat" to Patient Confidentiality 2Health News:Travellers Cautioned Over The Alternate Remedies For Malaria 2
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... delivers a new level of immunodiagnostic productivity. ... with any laboratory automation system. No-pause loading ... is the only immunoassay system with this ... system runs without any additional setup. Continuous ...
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: